ResMed launches improved nasal pillow
16 January, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) said the improvements made to its latest AirFit nasal pillows improve sleeping time and compliance in sleep-disordered breathing patients.
Ease into the new year with resolutions to grow the biotech industry
14 January, 2014The new year has dawned with news that biotechnology has become a "20-year overnight success", with The Age and The Sydney Morning Herald (4/1/14) reporting that "biotech has finally boomed". The article reported the array of successes of 2013, which included IPOs, four- to nine-fold surges in share prices for a number of companies, high-profile investors turning their attention to biotech and a steady flow of capital raisings that totalled $739.1 million (Biotech Daily, 2/1/14), the highest amount since 2007.
Aussie biotechs had an "outstanding" 2013
14 January, 2014 by Dylan Bushell-EmblingThe Australian listed biotech sector handily outperformed both the All Ordinaries and the Health Care Index last year, analysis from Bioscience Managers shows.
Analytica names new director
13 January, 2014 by Dylan Bushell-EmblingSeasoned biotechnology executive Carl Stubbings has today commenced his tenure as non-executive director of medical device company Analytica (ASX:ALT).
NSW launches second-round Medical Devices Fund
08 January, 2014 by Dylan Bushell-EmblingThe NSW Ministry of Health will soon start taking applications for the second round of a $5m per year grant program for medical device companies.
UQ boffins shrink C3a into a small molecule
12 December, 2013 by Dylan Bushell-EmblingUniversity of Queensland scientists have discovered a way of converting large proteins into small molecules suitable for drug development, while retaining their key properties.
AusBiotech wraps up a year of delivery for the industry
12 December, 2013As we head into Christmas and the New Year, the industry's ASX-listed market capitalisation sits just over $50 billion and there are signs that the IPO market is at last awakening from hibernation. The year has proven to be another solid period for the Australian biotechnology industry and for AusBiotech. During this time, AusBiotech was steadfast in its advocacy and active in its representation and support of the industry.
Avita CEO steps down after first strike
11 December, 2013 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has appointed interim replacements for its CEO and chairman and has started reviewing its remuneration policy following last month's 'first strike' vote.
Pharmaxis' Bronchitol to get Scottish NHS listing
11 December, 2013 by Dylan Bushell-EmblingThe Scottish Medicines Consortium (SMC) has accepted Bronchitol for use by the nation's National Health Service as an adjunct therapy in adult cystic fibrosis patients.
Review of R&D tax incentive bill
10 December, 2013The Tax Laws Amendment (Research and Development) Bill 2013 will proceed to the Senate after being debated and passed in the House of Representatives without amendment this week.
Australian medical devices seeking new markets in Asia
10 December, 2013 by Dr Anna LavelleThe scale and pace of Asia's transformation in recent years is unprecedented and provides opportunities and challenges as Australian companies seek to respond to the rising demands for medical devices in Asia.
Industry welcomes resurgence of IPOs
10 December, 2013With the initial public offering (IPO) of medical device distributor LifeHealthcare Group last week and the IPO launch of New Zealand-based Innate Immunotherapeutics the week prior, expectations are growing that we will see a reawakening of the biotechnology IPO market the coming year.
Revised code to increase investor confidence: promote it on your website
05 December, 2013Biotechnology companies are urged to display their adherence to the 'Code of Best Practice for Reporting by Life Science Companies' on the company website - either on the front page or on the investor relations landing page.
GI Dynamics, Mesoblast hail diabetes trial successes
04 December, 2013 by Dylan Bushell-EmblingGI Dynamics' (ASX:GID) and Mesoblast's (ASX:MSB) respective approaches to treating diabetes were able to reduce blood glucose levels while remaining well tolerated during separate trials.
Simavita raises $14m in Canadian IPO
03 December, 2013 by Dylan Bushell-EmblingAustralian incontinence sensor device developer Simavita has been cleared to list on Canada's TSXV market following a $14m IPO.
